Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats
Objective. To seek efficient aldose reductase inhibitors (ARIs) with excellent in vitro and in vivo biological activities against rat galactosemic cataract. Methods. The method was firstly optimized to screen strong ARIs from nonoriented synthetic compounds and natural extracts. Then, diosgenin was...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2017/7309816 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850165673264676864 |
|---|---|
| author | Lixia Ji Lixia Cheng Zhihong Yang |
| author_facet | Lixia Ji Lixia Cheng Zhihong Yang |
| author_sort | Lixia Ji |
| collection | DOAJ |
| description | Objective. To seek efficient aldose reductase inhibitors (ARIs) with excellent in vitro and in vivo biological activities against rat galactosemic cataract. Methods. The method was firstly optimized to screen strong ARIs from nonoriented synthetic compounds and natural extracts. Then, diosgenin was assessed on osmotic expansion of primarily cultured lens epithelial cells (LECs) induced by galactose (50 mM). Diosgenin was administered to galactosemic rats by oral (100 and 200 mg/kg) or direct drinking (0.1%) to evaluate its anticataract effects. Results. Diosgenin was found as the strongest ARI with IC50 of 4.59 × 10−6 mol/L. Diosgenin (10 μM) evidently inhibited the formation of tiny vacuoles and upregulation of AR mRNA in LECs. In vivo, diosgenin delayed lens opacification, inhibited the increase of ratio of lens weight to body weight, and decreased AR activity, galactitol level, and AR mRNA expression, especially in the diosgenin drinking (0.1%) group. Conclusions. Diosgenin was an efficient ARI, which not only significantly decreased the LECs’ osmotic expansion in vitro but also markedly delayed progression of rat galactosemic cataract in vivo. Thus, diosgenin rich food can be recommended to diabetic subjects as dietary management to postpone the occurrence of sugar cataract, and diosgenin deserves further investigation for chronic diabetic complications. |
| format | Article |
| id | doaj-art-ee82bf4599f14968ad312eff3be0e0d7 |
| institution | OA Journals |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-ee82bf4599f14968ad312eff3be0e0d72025-08-20T02:21:41ZengWileyJournal of Diabetes Research2314-67452314-67532017-01-01201710.1155/2017/73098167309816Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in RatsLixia Ji0Lixia Cheng1Zhihong Yang2Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, ChinaDepartment of Endocrinology, Weifang People’s Hospital, Weifang, ChinaDepartment of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, ChinaObjective. To seek efficient aldose reductase inhibitors (ARIs) with excellent in vitro and in vivo biological activities against rat galactosemic cataract. Methods. The method was firstly optimized to screen strong ARIs from nonoriented synthetic compounds and natural extracts. Then, diosgenin was assessed on osmotic expansion of primarily cultured lens epithelial cells (LECs) induced by galactose (50 mM). Diosgenin was administered to galactosemic rats by oral (100 and 200 mg/kg) or direct drinking (0.1%) to evaluate its anticataract effects. Results. Diosgenin was found as the strongest ARI with IC50 of 4.59 × 10−6 mol/L. Diosgenin (10 μM) evidently inhibited the formation of tiny vacuoles and upregulation of AR mRNA in LECs. In vivo, diosgenin delayed lens opacification, inhibited the increase of ratio of lens weight to body weight, and decreased AR activity, galactitol level, and AR mRNA expression, especially in the diosgenin drinking (0.1%) group. Conclusions. Diosgenin was an efficient ARI, which not only significantly decreased the LECs’ osmotic expansion in vitro but also markedly delayed progression of rat galactosemic cataract in vivo. Thus, diosgenin rich food can be recommended to diabetic subjects as dietary management to postpone the occurrence of sugar cataract, and diosgenin deserves further investigation for chronic diabetic complications.http://dx.doi.org/10.1155/2017/7309816 |
| spellingShingle | Lixia Ji Lixia Cheng Zhihong Yang Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats Journal of Diabetes Research |
| title | Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats |
| title_full | Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats |
| title_fullStr | Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats |
| title_full_unstemmed | Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats |
| title_short | Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats |
| title_sort | diosgenin a novel aldose reductase inhibitor attenuates the galactosemic cataract in rats |
| url | http://dx.doi.org/10.1155/2017/7309816 |
| work_keys_str_mv | AT lixiaji diosgeninanovelaldosereductaseinhibitorattenuatesthegalactosemiccataractinrats AT lixiacheng diosgeninanovelaldosereductaseinhibitorattenuatesthegalactosemiccataractinrats AT zhihongyang diosgeninanovelaldosereductaseinhibitorattenuatesthegalactosemiccataractinrats |